Pharmacotherapy for Sydenham’s chorea: where are we and where do we need to be?

References

• Kyle K, Bordelon Y, Venna N, et al. Autoimmune and paraneoplastic chorea: a review of the literature. Front Neurol. 2022;13:829076.
   PubMed Web of Science ®Google Scholar
• Cardoso F. Chorea: non-genetic causes. Curr Opin Neurol. 2004;17(4):433–436.
   PubMed Web of Science ®Google Scholar
• Cardoso F. Sydenham’s chorea. 2011. DOI:10.1016/B978-0-444-52014-2.00014-8
   Google Scholar
• Fusco C, Ucchino V, Frattini D, et al. Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham’s chorea. Eur J Paediatr Neurol. 2012;16(4):373–378. DOI:10.1016/j.ejpn.2011.12.005
   PubMed Web of Science ®Google Scholar
• Ekici A, Yakut A, Yimenicioglu S, et al. Clinical and neuroimaging findings of Sydenham’s chorea. Iran J Pediatr. 2014 Jun;24(3):300–6.
   Web of Science ®Google Scholar
• Bovenzi R, Conti M, Cerroni R, et al. Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. Neurol Sci. 2022;43(1):387–392. DOI:10.1007/s10072-021-05332-w
   PubMed Web of Science ®Google Scholar
• Cardoso F. Sydenham’s chorea. Curr Treat Options Neurol. 2008;10(3):230–235.
   PubMed Web of Science ®Google Scholar
• Orsini A, Foiadelli T, Magistrali M, et al. A nationwide study on Sydenham’s chorea: clinical features, treatment and prognostic factors: a multicenter cohort study on Sydenham’s chorea. Eur J Paediatr Neurol. 2022;36:1–6.
   PubMed Web of Science ®Google Scholar
• Depietri G, et al. Therapeutic aspects of Sydenham’s Chorea: an update. Acta Biomed. 2022;92:e2021414.
   PubMedGoogle Scholar
• Cardoso F, Vargas AP, Oliveira LD, et al. Persistent Sydenham’s chorea. Mov Disord. 1999;14(5):805–807. DOI:10.1002/1531-8257(199909)14:5<805::AID-MDS1013>3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Depietri G. Therapeutic aspects of Sydenham’s Chorea: an update. Acta Biomed. 2021. 10.23750/abm.v92iS4.12663.
   Google Scholar
• Fusco C, Spagnoli C. Corticosteroid treatment in Sydenham’s chorea. Eur J Paediatr Neurol. 2018;22(2):327–331.
   PubMed Web of Science ®Google Scholar
• Teixeira AL, Vasconcelos LP, Nunes MDCP, et al. Sydenham’s chorea: from pathophysiology to therapeutics. Expert Rev Neurotherapeutics. 2021;21(8):913–922.
   PubMed Web of Science ®Google Scholar
• Maia DP, Teixeira AL, Cunningham MCQ, et al. Obsessive compulsive behavior, hyperactivity, and attention deficit disorder in Sydenham chorea. Neurology. 2005;64(10):1799–1801.
   PubMed Web of Science ®Google Scholar
• Bonthius DJ, Karacay B. Sydenham’s chorea: not gone and not forgotten. Semin Pediatr Neurol. 2003;10(1):11–19.
   PubMedGoogle Scholar
• Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurotherapeutics. 2018;18(1):51–63.
   PubMed Web of Science ®Google Scholar
• Miranda M, Walker RH, Saez D, et al. Severe Sydenham’s chorea (chorea paralytica) successfully treated with plasmapheresis. J Clin Mov Disord. 2015;2(1). DOI:10.1186/s40734-014-0012-1
   PubMedGoogle Scholar
• Garvey MA, Snider LA, Leitman SF, et al. Treatment of sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol. 2005;20(5):424–429. DOI:10.1177/08830738050200050601
   PubMed Web of Science ®Google Scholar
• Teixeira AL, Cardoso F, Souza ALS, et al. Increased serum concentrations of monokine induced by interferon-γ/CXCL9 and interferon-γ-inducible protein 10/CXCL-10 in Sydenham’s chorea patients. J Neuroimmunol. 2004;150(1–2):157–162.
   PubMed Web of Science ®Google Scholar
• de L Torres KC, et al. Persistent Sydenham’s chorea is not associated with sustained lymphocyte dysfunction. Arq Neuropsiquiatr. 2016; DOI:10.1590/0004-282X20150179
   Web of Science ®Google Scholar
• SL D, HS S. Treatment of Sydenham’s Chorea: a Review of the current evidence. Tremor Other Hyperkinet Mov (N Y). 2017;7(0):456.
   PubMedGoogle Scholar
• Tochen L, Singer HS. Tourette syndrome and tic disorders. 2016;p. 951–970. DOI:10.1016/B978-0-12-802206-1.00048-9
   Google Scholar
• Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham Chorea. Arch Neurol. 2004;61(8). DOI:10.1001/archneur.61.8.1261
   PubMedGoogle Scholar
• Cunningham MCQS, Maia DP, Teixeira AL, et al. Sydenham’s chorea is associated with decreased verbal fluency. Parkinsonism Relat Disord. 2006;12(3):165–167.
   PubMed Web of Science ®Google Scholar
• Cavalcanti A, Hilário MOE, Dos Santos FH, et al. Subtle cognitive deficits in adults with a previous history of Sydenham’s chorea during childhood. Arthritis Care Res (Hoboken). 2010;62(8):1065–1071.
   PubMed Web of Science ®Google Scholar
• Beato R, Maia DP, Teixeira AL, et al. Executive functioning in adult patients with Sydenham’s chorea. Mov Disord. 2010;25(7):853–857.
   PubMed Web of Science ®Google Scholar
• Johnson N, Phillips M. Rayyan for systematic reviews. J Electron Resour Librariansh. 2018;30(1):46–48.
   Google Scholar
• Vale TC, Cardoso F. Chorea: a Journey through History. Tremor Other Hyperkinet Mov. 2015;5(0):5.
   Google Scholar
• Walker K, Brink A, Lawrenson J, et al. Treatment of Sydenham chorea with intravenous immunoglobulin. J Child Neurol. 2012;27(2):147–155. DOI:10.1177/0883073811414058
   PubMed Web of Science ®Google Scholar
• WHO. WHO technical report series 908. J Pharm Sci. 2003.
   Google Scholar
• Yilmaz S, JW M. Treatment of chorea in childhood. Pediatr Neurol. 2020;102:10–19.
   PubMed Web of Science ®Google Scholar
• Marijon E, Mirabel M, Celermajer DS, et al. Rheumatic heart disease. Lancet. 2012 Mar;379(9819):953–964.
   PubMed Web of Science ®Google Scholar
• Peña J, Mora E, Cardozo J, et al. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham´s chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr. 2002;60(2B):374–377.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Brk K, Oertel WH. Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother. 2011;12(1):63–72.
   PubMed Web of Science ®Google Scholar
• Genel F, Arslanoglu S, Uran N, et al. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24(2):73–76.
   PubMed Web of Science ®Google Scholar
• Mari L, Placidi F, Romigi A, et al. Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? Neurol Sci. 2022;43(3):1993–2001. DOI:10.1007/s10072-021-05542-2
   PubMed Web of Science ®Google Scholar
• Harel L, Zecharia A, Straussberg R, et al. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol. 2000;23(2):147–151.
   PubMed Web of Science ®Google Scholar
• Roig M, Montserrat L, Gallart A. Carbamazepine: an alternative drug for the treatment of nonhereditary chorea. Pediatrics. 1988;82(3):492–495.
   PubMed Web of Science ®Google Scholar
• Şahin S, Cansu A. A new alternative drug with fewer adverse effects in the treatment of Sydenham chorea: levetiracetam efficacy in a child. Clin Neuropharmacol. 2015;38(4):144–146.
   PubMed Web of Science ®Google Scholar
• Direk M, Epcacan S, Epcacan Z, et al. Efficacy of levetiracetam in the treatment of Sydenham chorea. Pediatr Int. 2020;62(11):1264–1268.
   PubMed Web of Science ®Google Scholar
• Işıkay S, Yılmaz K. Oxcarbazepine may be useful in Sydenham chorea. Turkish Archives Of Pediatrics. 2021;56(6):648–649.
   PubMedGoogle Scholar
• Teixeira AL. Sydenham’s chorea may be a risk factor for drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2003;74(9):1350–1351.
   PubMed Web of Science ®Google Scholar
• Demiroren K, Yavuz H, Cam L, et al. Sydenham’s chorea: a clinical follow-up of 65 patients. J Child Neurol. 2007;22(5):550–554.
   PubMed Web of Science ®Google Scholar
• Sethi S, Setiya R, Lallar K. Successful treatment of Sydenham chorea with olanzapine. J Paediatr Neurol. 2006. DOI:10.1055/s-0035-1557322
   Google Scholar
• Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509–1523.
   PubMed Web of Science ®Google Scholar
• Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord. 2006;21(11):1966–1972.
   PubMed Web of Science ®Google Scholar
• Schirinzi T, et al. Phenomenology and clinical course of movement disorder in GNAO1 variants: results from an analytical review. In Parkinsonism and related disordersVol. 61 2019 Apr Elsevier Ltd: p. 19–25. DOI:10.1016/j.parkreldis.2018.11.019
   Google Scholar
• Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10(17):2883–2896.
   PubMed Web of Science ®Google Scholar
• Shen V, Clarence-Smith K, Hunter C, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington’s and other diseases. Tremor Other Hyperkinet Mov. 2013;3(0):03.
   Google Scholar
• Hawkes CH, Nourse CH. Tetrabenazine in Sydenham’s chorea. Br Med J. 1977;1(6073):1391–1392.
   PubMedGoogle Scholar
• Harries-Jones R, Gibson JG. Successful treatment of refractory Sydenham’s chorea with pimozide. J Neurol Neurosurg Psychiatry. 1985;48(4):390.
   PubMed Web of Science ®Google Scholar
• Zaki SA, Lad P, Shanbag V. Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea. Indian J Pharmacol. 2011;43(5):601.
   PubMed Web of Science ®Google Scholar
• Kirvan CA, Swedo SE, Heuser JS, et al. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9(7):914–920.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Maia D, Cunningham MCQS, et al. Treatment of Sydenham chorea with corticosteroids. Mov Disord. 2003;18(11):1374–1377.
   PubMed Web of Science ®Google Scholar
• Feinstein E, Walker R. An Update on the Treatment of Chorea. Curr Treat Options Neurol. 2018;20(10):44.
   PubMed Web of Science ®Google Scholar
• Loechelt BJ, Green M, Gottlieb PA, et al. Screening and monitoring for infectious complications when immunosuppressive agents are studied in the treatment of autoimmune disorders. J Pediatric Infect Dis Soc. 2015;4(3):198–204. DOI:10.1093/jpids/piu055
   PubMed Web of Science ®Google Scholar
• Paz JA, Silva CAA, Marques-Dias MJ. Randomized double-blind study with prednisone in sydenham’s chorea. Pediatr Neurol. 2006;34(4):264–269. DOI:10.1016/j.pediatrneurol.2005.08.028
   PubMed Web of Science ®Google Scholar
• Favaretto E, Gortani G, Simonini G, et al. Preliminary data on prednisone effectiveness in children with Sydenham chorea. Eur J Pediatr. 2020;179(6):993–997. DOI:10.1007/s00431-020-03574-y
   PubMed Web of Science ®Google Scholar
• Massell BF, Warren JE, Sturgis GP, et al. The clinical response of rheumatic fever and acute carditis to ACTH. N Engl J Med. 1950;242(18):692–698.
   PubMed Web of Science ®Google Scholar
• Aronson N, Douglas HS, Lewis JM. Cortisone in sydenham’s chorea: report of two cases. J Am Med Assoc. 1951;145(1):30.
   PubMed Web of Science ®Google Scholar
• SCHWARZ H. Chorea gravis (Sydenham’s chorea) treated with cortisone and ascorbic acid. Can Med Assoc J. 1951 Aug;65(2):150–151.
   PubMed Web of Science ®Google Scholar
• Schwartzman J, Zaontz JB, Lubow H. Chorea minor. Preliminary report on six patients treated with combined ACTH and cortisone. J Pediatr. 1953;43(3):278–289.
   PubMed Web of Science ®Google Scholar
• Ainger LE, Ely RS, Done AK, et al. Sydenham’s Chorea: iI. Effects of HORMONE THERapy. AMA Am J Dis Child. 1955. DOI:10.1001/archpedi.1955.02050110694010
   Google Scholar
• Green LN. Corticosteroids in the treatment of Sydenham’s Chorea. Arch Neurol. 1978;35(1):53–54.
   PubMedGoogle Scholar
• De Queiroz Campos Araújo AP, Pádua PAB, Maia Filho HS. Management of rheumatic chorea: an observational study. Arq Neuropsiquiatr. 2002. DOI:10.1590/s0004-282x2002000200008
   Web of Science ®Google Scholar
• Faustino PC, Terreri MTRA, da Rocha A, et al. Clinical, laboratory, psychiatric and magnetic resonance findings in patients with Sydenham chorea. Neuroradiology. 2003;45(7):456–462.
   PubMed Web of Science ®Google Scholar
• Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham’s chorea. Pediatr Neurol. 2005;32(3):205–207.
   PubMed Web of Science ®Google Scholar
• Tumas V, Caldas CT, Santos AC, et al. Sydenham’s chorea: clinical observations from a Brazilian movement disorder clinic. Parkinsonism Relat Disord. 2007 Jul;13(5):276–283. doi:10.1016/j.parkreldis.2006.11.010
   PubMed Web of Science ®Google Scholar
• Walker AR, Tani LY, Thompson JA, et al. Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids. J Paediatr. 2007;151(6):679–683.
   PubMed Web of Science ®Google Scholar
• Zuniga C, Diaz S, Farina A, et al. Remission of concomitant Henoch-Schöenlein purpura and Sydenham chorea after intravenous corticosteroids. Neurol India. 2009;57(1):55.
   PubMed Web of Science ®Google Scholar
• Pastore S, de Cunto A, Benettoni A, et al. The resurgence of rheumatic fever in a developed country area: the role of echocardiography. Rheumatology. 2011;50(2):396–400.
   PubMed Web of Science ®Google Scholar
• El Otmani H, Moutaouakil F, Fadel H, et al. Chorea paralytica: a videotape case with rapid recovery and good long-term outcome. Acta Neurol Belg. 2013;113(4):515–517.
   PubMed Web of Science ®Google Scholar
• Mehta S, Goyal MK, Kilbane C, et al. An unusual and intriguing presentation of sydenham’s chorea. Tremor Other Hyperkinet Mov. 2018;8(0):593.
   PubMedGoogle Scholar
• Illán Ramos M, Sagastizabal Cardelús B, García Ron A, et al. Chorea as the presenting feature of acute rheumatic fever in childhood; case reports from a low-prevalence European setting. BMC Infect Dis. 2021;21(1). DOI:10.1186/s12879-021-06005-x
   Web of Science ®Google Scholar
• Güven AS, Oflaz MB, Kaya A, et al. Resistant chorea successfully treated with intravenous immunoglobulin: a case report. J Pediatr Academy. 2021;117–120. DOI:10.51271/jpea-2021-0146
   Google Scholar
• Orsini A, Foiadelli T CC, Sica A, et al. Psychopathological impact in patients with history of rheumatic fever with or without sydenham’s chorea: a multicenter prospective study. Int J Environ Res Public Health. 2022;19(17):10586.
   PubMed Web of Science ®Google Scholar
• Van Immerzeel TD, Van Gilst RM, Hartwig NG. Beneficial use of immunoglobulins in the treatment of Sydenham chorea. Eur J Pediatr. 2010;169(9):1151–1154.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic ivig therapy. Neurotherapeutics. 2021;18(4):2397–2418.
   PubMed Web of Science ®Google Scholar
• Gregorowski C, Lochner C, Martin L, et al. Neuropsychological manifestations in children with sydenham’s chorea after adjunct intravenous immunoglobulin and standard treatment. Metab Brain Dis. 2016;31(1):205–212. DOI:10.1007/s11011-015-9681-1
   PubMed Web of Science ®Google Scholar
• Ali A, Anugwom GO, Rehman U, et al. Sydenham chorea managed with immunoglobulin in acute rheumatic fever. Cureus. 2021. DOI:10.7759/cureus.14990
   Web of Science ®Google Scholar
• Boersma NA, Schippers H, Kuijpers T, et al. Successful treatment of Sydenham’s chorea with intravenous immunoglobulin. BMJ Case Rep. 2016;bcr2015211673. DOI:10.1136/bcr-2015-211673
   PubMedGoogle Scholar
• Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9. DOI:10.3389/fimmu.2018.01299
   Web of Science ®Google Scholar
• Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Diseases. 2008;52(6):1180–1196.
   PubMed Web of Science ®Google Scholar
• Osman C, Jennings R, El-Ghariani K, et al. Plasma exchange in neurological disease. Pract Neurol. 2020;20(2):92–99.
   PubMedGoogle Scholar
• Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–150. DOI:10.1212/WNL.0000000000000570
   PubMed Web of Science ®Google Scholar
• Martino D, Schrag A, Anastasiou Z, et al. Association of group a streptococcus exposure and exacerbations of chronic tic disorders: a multinational prospective cohort study. Neurology. 2021;96(12):e1680–1693. DOI:10.1212/WNL.0000000000011610
   PubMed Web of Science ®Google Scholar
• Schrag A-E, Martino D, Wang H, et al. Lack of association of group a streptococcal infections and onset of TiCs. Neurology. 2022;98(11):e1175–1183. DOI:10.1212/WNL.0000000000013298
   PubMed Web of Science ®Google Scholar
• LI G. Pregnancy and movement disorders. Neurol Clin. 1994;12(3):497–508.
   PubMed Web of Science ®Google Scholar
• Baker JM, Hung AY. Movement disorders in women. Semin Neurol. 2017;37(06):653–660.
   PubMedGoogle Scholar
• Maia DP, Fonseca PG, Camargos ST, et al. Pregnancy in patients with Sydenham’s Chorea. Parkinsonism Relat Disord. 2012;18(5):458–461.
   PubMed Web of Science ®Google Scholar
• Pathania M, Upadhyaya S, Lali BS, et al. Chorea gravidarum: a rarity in west still haunts pregnant women in the east. BMJ Case Rep. 2013;2013(jun27 1):bcr2012008096.
   PubMedGoogle Scholar
• Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol. 2020;16(2):84–96.
   PubMed Web of Science ®Google Scholar
• Caviness JN, Muenter MD. An unusual cause of recurrent chorea. Mov Disord. 1991;6(4):355–357.
   PubMed Web of Science ®Google Scholar
• Hruska RE, Silbergeld EK. Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur J Pharmacol. 1980;61(4):397–400.
   PubMed Web of Science ®Google Scholar
• Kompoliti K, Comella CL, Jaglin JA, et al. Menstrual-related changes in motoric function in women with Parkinson’s disease. Neurology. 2000;55(10):1572–1575.
   PubMed Web of Science ®Google Scholar
• BJ R, WJ W. Chorea gravidarum. Handb Clin Neurol. 2011;100:231–235.
   PubMedGoogle Scholar
• Kranick SM, Mowry EM, Colcher A, et al. Movement disorders and pregnancy: a review of the literature. Mov Disord. 2010;25(6):665–671.
   PubMed Web of Science ®Google Scholar
• Sosa BO, Toral JAB. Identifying the aetiology of sudden acute abnormal involuntary movements in a primigravid. BMJ Case Rep. 2018;11(1):e227112.
   PubMedGoogle Scholar
• Bovenzi R, Schirinzi T, Pierantozzi M, et al. Clinical course of paroxysmal dyskinesias throughout pregnancy. Parkinsonism Related Disord. 2020;80:19–20.
   PubMed Web of Science ®Google Scholar
• Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf. 2005;4(2):345–353.
   PubMedGoogle Scholar
• Robottom BJ, Factor SA, Weiner WJ. Movement disorders emergencies part 2: hyperkinetic disorders. Arch Neurol. 2011;68(6). DOI:10.1001/archneurol.2011.117
   Google Scholar
• Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Women’s Health. 2010;6(3):431–442.
   PubMedGoogle Scholar
• Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489–502.
   PubMed Web of Science ®Google Scholar
• SCHWARZ H, SAINT-VICTOR HD. Cortisone and ascorbic acid in chorea gravidarum (Sydenham’s chorea). Can Med Assoc J. 1952 Jun;66(6):583–585.
   Web of Science ®Google Scholar
• Rengifo-Quintero LJ, Beltrán-Avendaño MA. Corea Gravídica: reporte de caso y revisión de la literatura. Revista Colombiana de Obstetricia y Ginecología. 2019;70(3):189–194.
   PubMedGoogle Scholar
• Pathania M, Lali BS, Yadav NK, et al. Demonstration of choreic movements in a case of chorea gravidarum. BMJ Case Rep. 2013;2013(feb15 1):bcr2012008234.
   PubMedGoogle Scholar
• Gawande M, Ghike S, Jain S. A rare case of chorea gravidarum. J South Asian Federa Obstet Gynaecol. 2010;2(2):145–146.
   Google Scholar
• Walker K, Lawrenson J, JM W. Sydenham’s chorea–clinical and therapeutic update 320 years down the line. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. Vol. 96, No. 9. South Africa. 2006. p. 906–912.
   Google Scholar
• Teixeira AL, Maia DP, Cardoso F. UFMG Sydenham’s Chorea Rating Scale (USCRS): reliability and consistency. Mov Disord. 2005. DOI:10.1002/mds.20377
   Web of Science ®Google Scholar
• Rafeek RAM, Sikder S, Hamlin AS, et al. Requirements for a robust animal model to investigate the disease mechanism of autoimmune complications associated with ARF/RHD. Front Cardiovasc Med. 2021;8. DOI:10.3389/fcvm.2021.675339
   Web of Science ®Google Scholar
• Chain JL, Alvarez K, Mascaro-Blanco A, et al. Autoantibody biomarkers for basal ganglia encephalitis in Sydenham chorea and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections. Front Psychiatry. 2020;11. DOI:10.3389/fpsyt.2020.00564
   PubMed Web of Science ®Google Scholar